Back to Feed
总结
据路透等媒体报道，诺和诺德新推出的Wegovy口服版减重药在上市最初几天录得3,071张处方，显示早期需求表现“稳健”。消息带动公司股价在美股交易中上涨约5%。处方开局数据被视为检验口服减重药市场接受度、后续放量与公司收入贡献的重要信号，也影响投资者对其减重产品线竞争力的预期。
正文
Novo Nordisk wins 3,071 prescriptions for Wegovy pill (NVO:NYSE) Seeking Alpha Novo's Wegovy pill tracks 3,071 prescriptions in first days of launch Reuters Novo Nordisk shares rise 5% after Wegovy obesity pill has 'solid' launch CNBC Lubbock Doctor compares weight loss injections to new pills KCBD Novo Nordisk's Wegovy Weight Loss Pill Has a Strong Launch-and Other Reasons the Stock Is Rising Barron's
发布时间：